Bioporto: It’s a great start to 2016
Denmark’s Bioporto announced a distribution deal with one of the major players in the medtech arena, Germany’s Siemens Healthcare, this week. The deal has a huge strategic impact, says Bioporto’s CEO.
BY ELIZABETH MØNSTED JOHANSEN
Relations between Bioporto and Siemens Healthcare have been a bit tense in the past, as the Germans cut short a deal with the Danes for its NGAL test to diagnose acute kidney injury in late 2012. But another chapter was added to the story in the beginning of the week as Bioporto said it had once again struck a strategically crucial pact with Siemens.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto kick-starts kidney venture in Chicago
For abonnenter
Bioporto wants to build US organization
For abonnenter
